Insulin Pump to Multiple Daily Injection Transition Clinical Trial

Second generation long acting insulin, insulin degludec, has been shown to improve glycemic control and reduce hypoglycemia in patients with type 1 diabetes and insulin treated type 2 diabetes. However, it takes about 48 hours before glycemic benefits are noticeable. Therefore, transition from insulin pump to multiple daily injection using insulin degludec is associated with hyperglycemia during first 48 hours of transition. Considering this, this study proposes to evaluate an investigational strategy to improve glycemic control during transition from insulin pump to multiple daily injections using insulin degludec and insulin aspart.

Inclusion criteria

• Age ≥18 years and ≤ 65 years
• Patients with T1D diagnosed for at least 12 months
• Point-of-care HbA1c levels between ≥6.5% and ≤ 8.5%
• Patients on CSII (any insulin pump) for at least past 6 months
• Willing and able to wear a blinded CGM during the time of study period
• Willing to perform self-monitoring of blood glucose (SMBG) at least 4 times a day
• Ability to provide informed consent before any trial-related activities
• Not willing to or plan any travel out of Colorado during the 3 weeks of study period
• Willing to use insulin degludec in the morning once a day

Exclusion criteria

• Age <18 years and > 65years
• HbA1c >8.5 % at screening
• Less than 12 months of insulin treatment
• Patients on 670G or Tandem Control IQ (Medtronic and Tandem Hybrid Closed-loop systems) and not willing use manual mode during the study period
• Patients with T1D using any glucose lowering medications other than insulin
• Pregnancy, breast feeding, and positive pregnancy test during screening
• Women of childbearing age wanting to become pregnant or not using adequate contraceptive measures
• Current or recent (< 2 weeks prior to visit 1) use of any steroidal medication, or anticipated steroidal treatment, during the study period
• eGFR below 45 ml/min/1.73 m^2 using MDRD formula
• History of severe hypoglycemia in the previous 3 months
• History of diabetic ketoacidosis (DKA) requiring hospitalization in the past 3 months
• History of allergy to any form of insulin or its excipients
• History of allergy to adhesives
• Unwilling to use blinded CGM during the study period
• Unwilling to perform SMPG at least 4 times a day
• Known history of alcohol abuse or illicit drug use within 6 months prior to screening
• Use of investigational drugs within 5 half-lives prior to screening
• Participation to other study trials during the study period
• Elevated liver enzymes (AST and ALT) 3 times the upper limit of normal
• Hypoglycemia unawareness defined as GOLD score ≥4 [20]
• Any comorbidities or medical conditions that make a person unfit for the study at the discretion of the investigators
• Anticipated travel across different time zones (difference greater than 4 hours) or anticipated change in physical activities or diet at the discretion of the investigators.